- PaulCraigRoberts.org - https://www.paulcraigroberts.org -

The Covid Pandemic Was Entirely Unnecessary. Cures were available. The medical profession is responsible for the murders of huge and growing numbers of people.

The Covid Pandemic Was Entirely Unnecessary. Cures were available. The medical profession is responsible for the murders of huge and growing numbers of people.

Paul Craig Roberts

As I wrote not long after the “Covid pandemic” hype was underway, there were two known preventatives and cures: HCQ and Ivermectin. This known medical fact had to be suppressed by Fauci, Big Pharma, and their political allies. Otherwise in the presence of cures, the emergency use authorization of the untested and extremely dangerous Covid “vaccine” could not be granted.

As for unspecified reasons getting the entire world population “vaccinated” was the goal, the cures and the medical doctors and scientists who recommended them were suppressed.

Consequently, people all over the world are dropping dead daily and others are burdened with lifetime health injuries from the “vaccine.”

The Covid vaccination program is the worst crime ever inflicted on humanity. The people responsible should be arrested, tried, convicted and executed. Instead, they have made huge sums of money and awarded medals.

Hundreds of thousands of deaths in the US, and millions worldwide, could have been prevented by using Ivermectin (as was done in Peru and India).
Meanwhile, the AMA is taking away the licenses from physicians who prescribe Ivermectin and save lives.

https://www.theblaze.com/news/ivermectin-covid-treatment-new-study [1]

Ivermectin reduces COVID death risk by 92%, peer-reviewed study finds
News
Paul Sacca
September 03, 2022

A new peer-reviewed study found that regular use of ivermectin reduced the risk of dying from COVID-19 by 92%.
The large study was conducted by Flávio A. Cadegiani, MD, MSc, PhD. Cadegiani is a board-certified endocrinologist with a master’s degree and doctorate degree in clinical endocrinology.
The peer-reviewed study was published on Wednesday by the online medical journal Cureus. The study was conducted on a strictly controlled population of 88,012 people from the city of Itajaí in Brazil.
Individuals who used ivermectin as prophylaxis or took the medication before being infected by COVID experienced significant reductions in death and hospitalization.
According to the study, those who took ivermectin regularly had a 92% reduction in their COVID death risk compared to non-users and 84% less than irregular users.
“The hospitalization rate was reduced by 100% in regular users compared to both irregular users and non-users,” the study stated.
The impressive reduction for regular ivermectin users was evident despite the regular users being at a higher risk for COVID deaths. The regular users were older and had a higher prevalence of type 2 diabetes and hypertension than irregular and non-users.

Irregular users of ivermectin had a 37% lower mortality rate reduction than non-users.

The study defined regular users as those who used more than 30 tablets of ivermectin over five months. The dosage of ivermectin was determined by body weight, but “most of the population used between two and three tablets daily for two days, every 15 days.”
“Non-use of ivermectin was associated with a 12.5-fold increase in mortality rate and a seven-fold increased risk of dying from COVID-19 compared to the regular use of ivermectin,” the study read. “This dose-response efficacy reinforces the prophylactic effects of ivermectin against COVID-19.”
Cadegiani believes the study showed a “dose-response effect” – which means that increasing levels of ivermectin decreased the risk of hospitalization and death from COVID-19.
Cadegiani wrote on Twitter, “An observational study with the size and level of analysis as ours is hardly achieved and infeasible to be conducted as a randomised clinical trial. Conclusions are hard to be refuted. Data is data, regardless of your beliefs.”

https://www.cureus.com/articles/111851-regular-use-of-ivermectin-as-prophylaxis-for-covid-19-led-up-to-a-92-reduction-in-covid-19-mortality-rate-in-a-dose-response-manner-results-of-a-prospective-observational-study-of-a-strictly-controlled-population-of-88012-subjects?email_share=true&expedited_modal=true [2]

Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects
Lucy Kerr, Fernando Baldi, Raysildo Lobo, Washington Luiz Assagra, Fernando Carlos Proença, Juan J. Chamie, Jennifer A. Hibberd, Pierre Kory, Flavio A. Cadegiani

Published: August 31, 2022 (see history)
DOI: 10.7759/cureus.28624
Cite this article as: Kerr L, Baldi F, Lobo R, et al. (August 31, 2022) Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects. Cureus 14(8): e28624. doi:10.7759/cureus.28624

Abstract
Background
We have previously demonstrated that ivermectin used as prophylaxis for coronavirus disease 2019 (COVID-19), irrespective of the regularity, in a strictly controlled citywide program in Southern Brazil (Itajaí, Brazil), was associated with reductions in COVID-19 infection, hospitalization, and mortality rates. In this study, our objective was to determine if the regular use of ivermectin impacted the level of protection from COVID-19 and related outcomes, reinforcing the efficacy of ivermectin through the demonstration of a dose-response effect.
Methods
This exploratory analysis of a prospective observational study involved a program that used ivermectin at a dose of 0.2 mg/kg/day for two consecutive days, every 15 days, for 150 days. Regularity definitions were as follows: regular users had 180 mg or more of ivermectin and irregular users had up to 60 mg, in total, throughout the program. Comparisons were made between non-users (subjects who did not use ivermectin), and regular and irregular users after multivariate adjustments. The full city database was used to calculate and compare COVID-19 infection and the risk of dying from COVID-19. The COVID-19 database was used and propensity score matching (PSM) was employed for hospitalization and mortality rates.
Results
Among 223,128 subjects from the city of Itajaí, 159,560 were 18 years old or up and were not infected by COVID-19 until July 7, 2020, from which 45,716 (28.7%) did not use and 113,844 (71.3%) used ivermectin. Among ivermectin users, 33,971 (29.8%) used irregularly (up to 60 mg) and 8,325 (7.3%) used regularly (more than 180 mg). The remaining 71,548 participants were not included in the analysis. COVID-19 infection rate was 49% lower for regular users (3.40%) than non-users (6.64%) (risk rate (RR): 0.51; 95% CI: 0.45-0.58; p < 0.0001), and 25% lower than irregular users (4.54%) (RR: 0.75; 95% CI: 0.66-0.85; p < 0.0001). The infection rate was 32% lower for irregular users than non-users (RR: 0.68; 95% CI: 0.64-0.73; p < 0.0001). Among COVID-19 participants, regular users were older and had a higher prevalence of type 2 diabetes and hypertension than irregular and non-users. After PSM, the matched analysis contained 283 subjects in each group of non-users and regular users, between regular users and irregular users, and 1,542 subjects between non-users and irregular users. The hospitalization rate was reduced by 100% in regular users compared to both irregular users and non-users (p < 0.0001), and by 29% among irregular users compared to non-users (RR: 0.781; 95% CI: 0.49-1.05; p = 0.099). Mortality rate was 92% lower in regular users than non-users (RR: 0.08; 95% CI: 0.02-0.35; p = 0.0008) and 84% lower than irregular users (RR: 0.16; 95% CI: 0.04-0.71; p = 0.016), while irregular users had a 37% lower mortality rate reduction than non-users (RR: 0.67; 95% CI: 0.40-0.99; p = 0.049). Risk of dying from COVID-19 was 86% lower among regular users than non-users (RR: 0.14; 95% CI: 0.03-0.57; p = 0.006), and 72% lower than irregular users (RR: 0.28; 95% CI: 0.07-1.18; p = 0.083), while irregular users had a 51% reduction compared to non-users (RR: 0.49; 95% CI: 0.32-0.76; p = 0.001). Conclusion Non-use of ivermectin was associated with a 12.5-fold increase in mortality rate and a seven-fold increased risk of dying from COVID-19 compared to the regular use of ivermectin. This dose-response efficacy reinforces the prophylactic effects of ivermectin against COVID-19.

Share this page
[3] [4] [5] [6]